公开(公告)号：US20240344030A1

公开(公告)日：2024-10-17

申请号：US18292670

申请日：2022-07-28

Applicant: Cartesian Therapeutics, Inc.

Inventor： Yi Zhang ,  C. Andrew Stewart ,  Metin Kurtoglu ,  Sjaji Daniel ,  Murat V. Kalayoglu ,  Minhtran Ngo Casi

IPC: C12N5/0775 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C12N15/85

CPC classification number: C12N5/0662 ,  C07K14/5434 ,  C07K14/7158 ,  C07K16/2809 ,  C07K16/2878 ,  C12N15/85 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/92 ,  C12N2800/107

Abstract: Provided here are cells engineered for therapeutic purposes to express multiple proteins, including an anti-BCMA (B cell maturation antigen), anti-CD3 bispecific antibody. Also provided are new anti-BCMA, anti-CD3 bispecific antibodies with associated sequences. Further disclosed is a mesenchymal stem cell (MSC) comprising an exogenous mRNA encoding an anti-BCMA and anti-CD3 antibody, and an exogenous mRNA encoding a single-chain interleukin-12 (IL-12) fusion protein.